Back to News
Market Impact: 0.25
Takeda's Zasocitinib Shows Superior Skin Clearance In Phase 3 Psoriasis Trial
Source: Nasdaq
Healthcare & BiotechProduct Launches
Takeda announced new data from three Phase 3 LATITUDE studies evaluating zasocitinib (TAK-279) in adults with moderate-to-severe plaque psoriasis. The article does not provide efficacy, safety, or statistical results, limiting assessment of the program's clinical or commercial significance.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.15
Ticker Sentiment
TAK0.45
More News
- Google rolls out Gemini 4 Argon, its most advanced AI model
- Meta stock enjoys best month since 2022 on AI momentum
- Huawei unveils Mate 90 phones, leans on homegrown chip design to offset US curbs
- Bloomberg Tech: OpenAI Seeks $30B as Trump Backs Safety Audits
- OpenAI’s $30B Bet, Trump’s AI Safety Shift and Apple’s Next Act
- Eli Lilly says closely watched combo obesity regimen boosts weight loss in mid-stage trial
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- AI in Asset Management: 2026 Statistics That Hold Up
- What is Broker Research and RMS Systems (And How to Actually Use Them)